drugset
drugset / Trial / NCT05890729

A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT05890729 ↗

Phase 1/2 Recruiting 94 enrolled Xentria, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis

Timeline

Start
2023-11-10
Primary completion
2029-05
Completion
2029-05

Drugs

EvaluationDrugModalityDoseRoute
Subject XTMAB-16 Unknown 2 mg/kg Other
Subject XTMAB-16 Unknown 4 mg/kg Other

Indications

pulmonary sarcoidosis